Massive necrosis (idiosyncratic; a dozen Japanese find out what was reallyin their Red Chinese holistic-wholesome weight-loss pills beside lotus leaves and chrysanthemum petals: Ann.
John D. Piette, Hema Datwani, Sofia Gaudioso, Stephanie M. Foster, Joslyn Westphal, William Perry, Joel Rodríguez-Saldaña, Milton O. Mendoza-Avelares, Nicolle Marinec. . (2012) Hypertension Management Using Mobile Technology and Home Blood Pressure Monitoring: Results of a Randomized Trial in Two Low/Middle-Income Countries. 18:8, 613-620.
Christopher Melby, Hunter Paris, Rebecca Foright, James Peth. . (2017) Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up?. 9:5, 468.
Taken together, these findings indicate that in obese persons who have lost weight, multiple compensatory mechanisms encouraging weight gain, which persist for at least 1 year, must be overcome in order to maintain weight loss. These mechanisms would be advantageous for a lean person in an environment where food was scarce, but in an environment in which energy-dense food is abundant and physical activity is largely unnecessary, the high rate of relapse after weight loss is not surprising. Furthermore, the activation of this coordinated response in people who remain obese after weight loss supports the view that there is an elevated body-weight set point in obese persons and that efforts to reduce weight below this point are vigorously resisted. In keeping with this theory, studies have shown that after adjustment for body composition, people whose weight is normal and those who are obese have similar energy requirements for weight maintenance and equivalent reductions in energy expenditure after weight loss. If this is the case, successful management of obesity will require the development of safe, effective, long-term treatments to counteract these compensatory mechanisms and reduce appetite. Given the number of alterations in appetite-regulating mechanisms that have been described so far, a combination of medications will probably be required. Several such combinations are undergoing evaluation, but none have been approved by the Food and Drug Administration. Bariatric surgery has well-documented favorable effects on appetite-mediating hormones, hunger, body weight, hypertension, dyslipidemia, type 2 diabetes, and mortality. However, because of the attendant costs and long waiting periods, bariatric surgery is not readily accessible to most people.
Christopher Montoya, Ethan Lazarus. . (2017) Maintaining Weight Loss by Decreasing Sedentary Time: A Patient and Physician’s Perspective. 34:4, 1007-1012.
In terms of the relation between education and various health risk factors - smoking, drinking, diet/exercise, use of illegal drugs, household safety, use of preventive medical care, and care for hypertension and diabetes - overall the results suggest very strong gradients where the better educated have healthier behaviors along virtually every margin, although some of these behaviors may also reflect differential access to care.
For 8 weeks, participants were instructed to replace all three of their daily meals with a very-low-energy dietary formulation (Optifast VLCD, Nestlé) and 2 cups of low-starch vegetables, according to the manufacturer's guidelines, which provided 2.1 to 2.3 MJ (500 to 550 kcal) per day. During weeks 9 and 10, participants who had lost 10% or more of their initial body weight were gradually reintroduced to ordinary foods, and weight was stabilized to avoid the potential confounding effect of active weight loss on hormone profiles. Meal replacements were stopped at the end of week 10.
The group touted the drug's benefits, which include weight loss of nearly 10 percent for most patients taking the drug over a year - the highest reduction reported with any recent diet pill. But panelists stressed that the drugmaker must be required to conduct a large, follow-up study of the pill's effects on the heart.
Barham K. Abu Dayyeh, Andres Acosta, Michael Camilleri, Manpreet S. Mundi, Elizabeth Rajan, Mark D. Topazian, Christopher J. Gostout. . (2017) Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. 15:1, 37-43.e1.
It uses phentermine, the appetite suppressant. The other drug is topiramate, an anticonvulsant sold by Johnson & Johnson as Topamax. Topiramate is believed to make patients feel more satiated, though it's unclear exactly how. J&J initially studied Topamax alone as a weight loss treatment but concluded the psychiatric side effects, such as memory loss and difficulty concentrating, were too significant.
Hunter L. Paris, Rebecca M. Foright, Kelsey A. Werth, Lauren C. Larson, Joseph W. Beals, Kimberly Cox-York, Christopher Bell, Christopher L. Melby. . (2016) Increasing energy flux to decrease the biological drive toward weight regain after weight loss – A proof-of-concept pilot study. 11, e12-e20.
- Perhaps the worst diet pill safety debacle came in the 1990s and involved the combination of phentermine and another weight loss drug marketed by Wyeth called fenfluramine. The combination of the two pills, dubbed fen-phen, was never approved by the FDA. But because the agency doesn't regulate doctors' decisions about prescribing various combinations of drugs, more than 18 million fen-phen prescriptions were written by 1996.
Christopher N. Ochner, Dulce M. Barrios, Clement D. Lee, F. Xavier Pi-Sunyer. . (2013) Biological mechanisms that promote weight regain following weight loss in obese humans. 120, 106-113.